Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Novartis meningitis vaccine initial data shows “greater protection”

Novartis meningitis vaccine initial data shows “greater protection”

7th May 2008

New data from a trial by Novartis of Menveo shows it could have potential to protect children from four types of meningitis from infancy through to adolescence, the company says.

The results from the phase III study indicate that it offers “greater protection” that the Sanofi Pasteur drug Menactra and could be the first such quadrivalent meningococcal vaccine.

It suggests millions of young children and teenagers up to the age of 18 around the world could benfit from the vaccine.

Bacterial meningitis, is an infection of the membrane around the brain and spinal cord; Menveo could also prevent sepsis, a serious blood infection.

The head-to-head trial results of Menveo compared to Menactra show adolescents immunised with Menveo generated higher levels of antibodies against all four serogroups.

Medical director of the Primary Physicians Research in Pittsburgh, Keith S Reisinger, said: “These data are encouraging because they show that Menveo may provide greater protection for the more than eight million infants and adolescents.”

According to NHS figures, there are up to 4,000 cases of meningitis reported a year in the UK.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.